← Back to Screener
Precision BioSciences, Inc. Common Stock (DTIL)
Price$7.53
Favorite Metrics
Price vs S&P 500 (26W)30.40%
Price vs S&P 500 (4W)3.14%
Market Capitalization$189.41M
P/E Ratio (Annual)19.04x
All Metrics
Book Value / Share (Quarterly)$3.83
P/TBV (Annual)1.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.93%
Cash Flow / Share (Quarterly)$-2.76
Price vs S&P 500 (YTD)81.49%
Net Profit Margin (TTM)-133.45%
EPS (TTM)$-5.13
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$-5.13
Revenue Growth (5Y)7.13%
EPS (Annual)$-3.56
ROI (Annual)-39.88%
Net Profit Margin (5Y Avg)-144.03%
Cash / Share (Quarterly)$4.80
Revenue Growth QoQ (YoY)5261.13%
P/E Normalized (Annual)19.04x
ROA (Last FY)-29.61%
Revenue Growth TTM (YoY)-50.12%
EBITD / Share (TTM)$-3.13
ROE (5Y Avg)-116.05%
Operating Margin (TTM)-152.30%
Cash Flow / Share (Annual)$-2.76
P/B Ratio2.05x
P/B Ratio (Quarterly)1.09x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)2.95x
Net Interest Coverage (TTM)-8.08x
ROA (TTM)-38.00%
EV / EBITDA (TTM)17.62x
EPS Incl Extra (Annual)$-3.56
Current Ratio (Annual)13.32x
Quick Ratio (Quarterly)12.97x
3-Month Avg Trading Volume0.26M
52-Week Price Return71.75%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$3.78
P/S Ratio (Annual)5.53x
Asset Turnover (Annual)0.22x
52-Week High$8.82
Operating Margin (5Y Avg)-120.10%
EPS Excl Extra (Annual)$-3.56
CapEx CAGR (5Y)-32.60%
Tangible BV CAGR (5Y)16.17%
26-Week Price Return34.39%
Quick Ratio (Annual)12.97x
13-Week Price Return88.67%
Total Debt / Equity (Annual)0.24x
Current Ratio (Quarterly)13.32x
Enterprise Value$100.988
Revenue / Share Growth (5Y)-28.21%
Asset Turnover (TTM)0.28x
Book Value / Share Growth (5Y)-31.45%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-136.03%
Cash / Share (Annual)$4.80
3-Month Return Std Dev77.32%
Net Income / Employee (TTM)$-1
ROE (Last FY)-49.57%
Net Interest Coverage (Annual)0.44x
EPS Basic Excl Extra (Annual)$-3.56
Receivables Turnover (TTM)40.36x
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-5.13
Receivables Turnover (Annual)40.36x
ROI (TTM)-64.92%
P/S Ratio (TTM)5.53x
Pretax Margin (5Y Avg)-105.97%
Revenue / Share (Annual)$2.67
Tangible BV / Share (Annual)$3.78
Price vs S&P 500 (52W)41.92%
Year-to-Date Return84.13%
5-Day Price Return15.88%
EPS Normalized (Annual)$-3.56
ROA (5Y Avg)-24.82%
Net Profit Margin (Annual)-133.45%
Month-to-Date Return39.27%
Cash Flow / Share (TTM)$-0.62
EBITD / Share (Annual)$-3.12
Operating Margin (Annual)-152.30%
LT Debt / Equity (Annual)0.24x
ROI (5Y Avg)-69.42%
LT Debt / Equity (Quarterly)0.24x
EPS Basic Excl Extra (TTM)$-5.13
P/TBV (Quarterly)1.10x
P/B Ratio (Annual)1.09x
Pretax Margin (TTM)-136.03%
Book Value / Share (Annual)$3.83
Price vs S&P 500 (13W)87.98%
Beta1.39x
P/FCF (Annual)2.10x
Revenue / Share (TTM)$1.79
ROE (TTM)-95.12%
52-Week Low$3.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.30
4.30
4.30
4.30
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DTILPrecision BioSciences, Inc. Common Stock | 5.53x | -50.12% | — | — | $7.53 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Precision BioSciences develops genome editing therapeutics based on its proprietary ARCUS platform. The platform's compact size enables efficient delivery to a wider range of cells and tissues using both viral and non-viral methods, potentially providing competitive advantages. The company applies ARCUS to create product candidates for human disease treatment and agricultural applications.